BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15195243)

  • 21. Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.
    Tedeschi R; Pin E; Martorelli D; Bidoli E; Marus A; Pratesi C; Bortolin MT; Zanussi S; Vaccher E; Dolcetti R; De Paoli P
    Clin Vaccine Immunol; 2007 Apr; 14(4):435-41. PubMed ID: 17329446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.
    Wong MM; Lye MS; Cheng HM; Sam CK
    Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.
    Fachiroh J; Prasetyanti PR; Paramita DK; Prasetyawati AT; Anggrahini DW; Haryana SM; Middeldorp JM
    J Clin Microbiol; 2008 Apr; 46(4):1374-80. PubMed ID: 18256216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
    Jiang SQ; Liu Q
    Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
    Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
    J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma.
    Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a multianalyte profiling assay and an enzyme-linked immunosorbent assay for serological examination of Epstein-Barr virus-specific antibody responses in diagnosis of nasopharyngeal carcinoma.
    Gu AD; Mo HY; Xie YB; Peng RJ; Bei JX; Peng J; Li MY; Chen LZ; Feng QS; Jia WH; Zeng YX
    Clin Vaccine Immunol; 2008 Nov; 15(11):1684-8. PubMed ID: 18768669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Fachiroh J; Paramita DK; Tan IB; Haryana SM; Middeldorp JM
    J Clin Microbiol; 2005 Jul; 43(7):3066-73. PubMed ID: 16002393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
    Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
    J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.
    Cheng WM; Chan KH; Chen HL; Luo RX; Ng SP; Luk W; Zheng BJ; Ji MF; Liang JS; Sham JS; Wang DK; Zong YS; Ng MH
    Int J Cancer; 2002 Feb; 97(4):489-92. PubMed ID: 11802211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.
    Mathew A; Cheng HM; Sam CK; Joab I; Prasad U; Cochet C
    Cancer Immunol Immunother; 1994 Jan; 38(1):68-70. PubMed ID: 8299121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.